### 2.2.1 In vitro and physico-chemical data

A literature search was performed to collect available information on physical chemical properties of midazolam. The obtained information from literature is summarized in the table below, and is used for model building.

| **Parameter**                         | **Unit**                   | **Value**        | Source                            | **Description**                                              |
| :------------------------------------ | -------------------------- | ---------------- | --------------------------------- | ------------------------------------------------------------ |
| MW                                    | g/mol                      | 325.78           | [DrugBank DB00683](#5-References) | Molecular weight                                             |
| pK<sub>a,base</sub>                   |                            | 6.2              | [Wang 2019](#5-References)        | Basic dissociation constant                                  |
| pK<sub>a,acid</sub>                   |                            | 10.95            | [Wang 2019](#5-References)        | Acid dissociation constant                                   |
| Solubility (pH)                       | mg/mL                      | 0.13<br />(5)    | [Heikkinen 2012](#5 References)   | Aqueous Solubility                                           |
|                                       |                            | 0.049<br />(6.5) | [Heikkinen 2012](#5 References)   | FaSSIF solubility                                            |
|                                       |                            | 0.09<br />(5)    | [Heikkinen 2012](#5 References)   | FeSSIF solubility                                            |
| logP                                  |                            | 3.53             | [Wang 2019](#5-References)        | Partition coefficient between octanol and water              |
|                                       |                            | 3.0              | [Dagenais 2009](#5-References)    | Partition coefficient between octanol and water              |
|                                       |                            | 3.37             | [Bolger 2006](#5-References)      | Partition coefficient between octanol and water              |
|                                       |                            | 3.1              | [Rodgers 2006](#5-References)     | Partition coefficient between octanol and water              |
| fu                                    | %                          | 3.1              | [Gertz 2010](#5-References)       | Fraction unbound in plasma                                   |
|                                       | %                          | 3.2              | [Wang 2019](#5-References)        | Fraction unbound in plasma                                   |
|                                       | %                          | 2.2              | [Lown 1995](#5-References)        | Fraction unbound in plasma                                   |
|                                       | %                          | 3.1              | [Björkman 2001](#5-References)    | Fraction unbound in plasma in men                            |
|                                       | %                          | 3.1              | [Björkman 2001](#5-References)    | Fraction unbound in plasma in women                          |
| V<sub>max</sub>, K<sub>m</sub> CYP3A4 | pmol/min/pmol,<br />µmol/L | 1.96<br />2.69   | [Galentin 2004](#5-References)    | CYP3A4 supersomes Michaelis-Menten kinetics (alpha-hydroxylation) |
| V<sub>max</sub>, K<sub>m</sub> CYP3A4 | pmol/min/mg<br />µmol/L    | 850<br />4       | [Bolger 2006](#5-References)      | CYP3A liver mircosomes Michaelis-Menten kinetics             |
| V<sub>max</sub>, K<sub>m</sub> CYP3A4 | nmol/min/mg<br />µmol/L    | 4.41<br />3.8    | [Ito 2003](#5-References)         | CYP3A liver mircosomes Michaelis-Menten kinetics (alpha-hydroxylation) |
| V<sub>max</sub>, K<sub>m</sub> CYP3A4 | nmol/min/mg<br />µmol/L    | 0.18<br />3.9    | [Patki 2003](#5-References)       | CYP3A liver mircosomes Michaelis-Menten kinetics (alpha-hydroxylation) |
| V<sub>max</sub>, K<sub>m</sub> CYP3A4 | pmol/min/pmol,<br />µmol/L | 5.23<br />2.16   | [Wang 2019](#5-References)        | CYP3A4 supersomes Michaelis-Menten kinetics (alpha-hydroxylation) |
| V<sub>max</sub>, K<sub>m</sub> UGT1A4 | pmol/min/mg<br />µmol/L    | 276<br />37.8    | [Klieber 2008](#5-References)     | UGT1A4 liver mircosomes Michaelis-Menten kinetics            |
| K<sub>D</sub> GABRG2                  | nmol/L                     | 1.8              | [Buhr 1997](#5-References)        | Binding affinity to GABRG2 (Gamma-Aminobutyric Acid Type A Receptor Subunit Gamma2) |

### 2.2.2 Clinical data

A literature search was performed to collect available clinical data on midazolam in adults. 

The following publications were found in adults for model building:

| Publication                   | Arm / Treatment / Information used for model building        |
| :---------------------------- | :----------------------------------------------------------- |
| [Hohmann 2015](#5-References) | Plasma PK profiles in healthy subjects with single dose administrations of midazolam solutions:<br />- intravenous 0.001 mg<br />- intravenous 1 mg<br />- oral 0.003 mg<br />- oral 3 mg |
| [Hyland 2009](#5-References)  | Quantification of direct UGT1A4-formed midazolam-*N*-glucuronide (in urine)  after administration of a 3 mg oral and 1 mg intravenous dose of midazolam. See table below for summary of data. |
| [Thummel 1996](#5-References) | Quantification of unchanged midazolam in urine after administration of a 2 mg oral and 1 mg intravenous dose of midazolam. See table below for summary of data. |
| [Ahonen 1995](#5-References)  | Plasma PK profiles in healthy subjects with single dose administrations of a midazolam 7.5 mg tablet (in the absence of itraconazole) |
| [Olkkola 1994](#5-References) | Plasma PK profiles in healthy subjects with single dose administrations of a midazolam 7.5 mg tablet (in the absence of itraconazole) |
| [Olkkola 1996](#5-References) | Plasma PK profiles in healthy subjects with single dose administrations of a midazolam 7.5 mg tablet (in the absence of itraconazole) |
| [Saari 2006](#5-References)   | Plasma PK profiles in healthy subjects with single dose administrations of a midazolam 7.5 mg tablet (in the absence of voriconazole) |
| [Link 2008](#5-References)    | Plasma PK profiles in healthy subjects with single dose administrations of a midazolam 7.5 mg tablet (in the absence of rifampicin) |



The following table shows the data from the excretion studies ([Thummel 1996](#5-References), [Hyland 2009](#5-References)) used for model building:

| Observer                                                     | Value |
| ------------------------------------------------------------ | ----- |
| Fraction excreted  to urine of unchanged midazolam after iv administration (female) | 0.27% |
| Fraction excreted  to urine of unchanged midazolam after iv administration (male) | 0.28% |
| Fraction excreted  to urine of unchanged midazolam after po administration (female) | 0.31% |
| Fraction excreted  to urine of unchanged midazolam after po administration (male) | 0.47% |
| Fraction metabolized UGT1A4 (to midazolam-*N*-glucuronide) after iv administration | 2.16% |
| Fraction metabolized UGT1A4 (to midazolam-*N*-glucuronide) after po administration | 1.29% |



The following dosing senarios were simulated and compared to respective data for model verification:

| Scenario                                                     | Data reference                       |
| ------------------------------------------------------------ | ------------------------------------ |
| iv 0.05 mg/kg (2 min)                                        | [Olkkola 1993](5-References)         |
| iv 0.05 mg/kg (30 min)                                       | [Gorski 1998](5-References)          |
|                                                              | [Gorski 2003](5-References)          |
|                                                              | [Quinney 2008](5-References)         |
| iv 0.05 mg/kg (bolus)                                        | [Szalat 2007](5-References)          |
| iv 0.075 mg/kg (1 min)                                       | [Allonen 1981](5-References)         |
|                                                              | [Swart 2002](5-References)           |
| iv 0.15 mg/kg (bolus)                                        | [Heizmann 1983](5-References)        |
| iv 1 mg (bolus)                                              | [Kharasch 1997](5-References)        |
|                                                              | [Kharasch 2004](5-References)        |
|                                                              | [Kharasch 2011](5-References)        |
|                                                              | [Phimmasone 2001](5-References)      |
|                                                              | [Shin 2013](5-References)            |
|                                                              | [Shin 2016](5-References)            |
| iv 2 mg (bolus)                                              | [Darwish 2008](5-References)         |
| iv 5 mg (30 sec)                                             | [Schwagmeier 1998](5-References)     |
| iv 5 mg (bolus)                                              | [Smith 1981](5-References)           |
| po 0.01 mg (solution)                                        | [Prueksaritanont 2017](5-References) |
| po 0.075 mg (solution)                                       | [Eap 2004](5-References)             |
| po 0.075 mg/kg (syrup)                                       | [Chung 2006](5-References)           |
| po 1 mg (solution)                                           | [van Dyk 2018](5-References)         |
| po 10 mg (solution)                                          | [Lam 2003](5-References)             |
|                                                              | [Smith 1981](5-References)           |
| po 10 mg (tablet)                                            | [Heizmann 1983](5-References)        |
|                                                              | [Smith 1981](5-References)           |
| po 15 mg (tablet)                                            | [Allonen 1981](5-References)         |
|                                                              | [Backman 1994](5-References)         |
|                                                              | [Backman 1996](5-References)         |
|                                                              | [Backman 1998](5-References)         |
|                                                              | [Bornemann 1986](5-References)       |
|                                                              | [Olkkola 1993](5-References)         |
|                                                              | [Yeates 1996](5-References)          |
|                                                              | [Zimmermann 1996](5-References)      |
| po 15 mg (tablet) - with 1h after  high-fat breakfast        | [Bornemann 1986](5-References)       |
| po 2 mg (solution)                                           | [Templeton 2010](5-References)       |
| po 2.5 mg (solution)                                         | [Okudaira 2007](5-References)        |
| po 20 mg (tablet)                                            | [Heizmann 1983](5-References)        |
| po 3 mg (solution)                                           | [Katzenmaier 2010](5-References)     |
|                                                              | [Kharasch 2004](5-References)        |
|                                                              | [Kharasch 2011](5-References)        |
|                                                              | [Markert 2013](5-References)         |
| po 3.5 mg (solution)                                         | [Quinney 2008](5-References)         |
| po 4 mg (solution)                                           | [Gorski 1998](5-References)          |
|                                                              | [Gorski 2003](5-References)          |
| po 40 mg (tablet)                                            | [Heizmann 1983](5-References)        |
| po 5 mg (solution)                                           | [Darwish 2008](5-References)         |
|                                                              | [Okudaira 2007](5-References)        |
|                                                              | [Tham 2006](5-References)            |
| po 6 mg (solution)                                           | [Greenblat 2003](5-References)       |
| po 7.5 mg (solution)                                         | [Eap 2004](5-References)             |
| po 8 mg (solution)                                           | [Gurley 2006](5-References)          |
|                                                              | [Gurley 2008a](5-References)         |
| Mikus 2017<br />(4 mg po solution,  followed by 2 mg iv administration 6 hours later) | [Mikus 2017](5-References)           |